These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27027250)

  • 1. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
    Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
    Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
    Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
    Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.
    Chen YT; Valent ET; van Beers EH; Kuiper R; Oliva S; Haferlach T; Chng WJ; van Vliet MH; Sonneveld P; Larocca A
    Int J Lab Hematol; 2022 Feb; 44(1):127-134. PubMed ID: 34448362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene signature combinations improve prognostic stratification of multiple myeloma patients.
    Chng WJ; Chung TH; Kumar S; Usmani S; Munshi N; Avet-Loiseau H; Goldschmidt H; Durie B; Sonneveld P
    Leukemia; 2016 May; 30(5):1071-8. PubMed ID: 26669975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
    Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
    J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.
    Papanikolaou X; Alapat D; Rosenthal A; Stein C; Epstein J; Owens R; Yaccoby S; Johnson S; Bailey C; Heuck C; Tian E; Joiner A; van Rhee F; Khan R; Zangari M; Jethava Y; Waheed S; Davies F; Morgan G; Barlogie B
    Leukemia; 2015 Aug; 29(8):1713-20. PubMed ID: 25753926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
    Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler GM; Benner A; Hundemer M; Rème T; Shaughnessy JD; Barlogie B; Bertsch U; Hillengass J; Ho AD; Pantesco V; Jauch A; De Vos J; Rossi JF; Möhler T; Klein B; Hose D
    Oncogene; 2009 Nov; 28(44):3866-79. PubMed ID: 19718049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
    Sarasquete ME; Martínez-López J; Chillón MC; Alcoceba M; Corchete LA; Paiva B; Puig N; Sebastián E; Jiménez C; Mateos MV; Oriol A; Rosiñol L; Palomera L; Teruel AI; González Y; Lahuerta JJ; Bladé J; Gutiérrez NC; Fernández-Redondo E; González M; San Miguel JF; García-Sanz R
    Br J Haematol; 2013 Oct; 163(2):223-34. PubMed ID: 23952215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
    Shaughnessy JD; Haessler J; van Rhee F; Anaissie E; Pineda-Roman M; Cottler-Fox M; Hollmig K; Zangari M; Mohiuddin A; Alsayed Y; Grazziutti M; Epstein J; Crowley J; Barlogie B
    Br J Haematol; 2007 Jun; 137(6):530-6. PubMed ID: 17489983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.
    Meißner T; Seckinger A; Hemminki K; Bertsch U; Foersti A; Haenel M; Duering J; Salwender H; Goldschmidt H; Morgan GJ; Hose D; Weinhold N
    BMC Med Genomics; 2015 Dec; 8():85. PubMed ID: 26714877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
    Hose D; Beck S; Salwender H; Emde M; Bertsch U; Kunz C; Scheid C; Hänel M; Weisel K; Hielscher T; Raab MS; Goldschmidt H; Jauch A; Moreaux J; Seckinger A
    J Hematol Oncol; 2019 Jun; 12(1):65. PubMed ID: 31242924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
    Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Verma A; McDonald EJ; Killick S; Hellström-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
    J Clin Oncol; 2013 Oct; 31(28):3557-64. PubMed ID: 24002510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-risk identification in multiple myeloma using a new 14-gene model.
    Chen T; Berno T; Zangari M
    Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
    Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
    Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
    Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
    Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
    Zhou Y; Nair B; Shaughnessy JD; Cartron MA; Haessler J; Anaissie E; van Rhee F; Crowley J; Barlogie B
    Br J Haematol; 2009 Jun; 145(5):637-41. PubMed ID: 19344415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
    Kuiper R; van Duin M; van Vliet MH; Broijl A; van der Holt B; El Jarari L; van Beers EH; Mulligan G; Avet-Loiseau H; Gregory WM; Morgan G; Goldschmidt H; Lokhorst HM; Sonneveld P
    Blood; 2015 Oct; 126(17):1996-2004. PubMed ID: 26330243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.